| Literature DB >> 28399831 |
Kazuichi Maruyama1, Yuko Maruyama2, Sunao Sugita3, Kazuhiko Mori2, Yu Yokoyama4, Shiho Sanuki-Kunimatsu4, Hiroko Nakagawa2, Shigeru Kinoshita2, Manabu Mochizuki5, Toru Nakazawa4.
Abstract
BACKGROUND: In Posner-Schlossman syndrome (PSS), which is characterized by recurrent unilateral attacks of ocular hypertension. Surgical treatment is sometimes necessary because intraocular pressure (IOP) cannot be controlled with anti-glaucoma medications. To identify the clinical features of Posner-Schlossman syndrome (PSS) indicative of the need for intraocular pressure (IOP)-controlling surgery.Entities:
Keywords: Corneal endothelial cell (CEC) density; Glaucoma surgery; Intraocular pressure (IOP); Polymerase chain reaction (PCR); Posner–Schlossman syndrome (PSS)
Mesh:
Year: 2017 PMID: 28399831 PMCID: PMC5387341 DOI: 10.1186/s12886-017-0438-y
Source DB: PubMed Journal: BMC Ophthalmol ISSN: 1471-2415 Impact factor: 2.209
Fig. 1Specular microscope photographs of (a) a non-affected eye and (b) an affected eye. Gonioscopic slit lamp photographs of (c) a non-affected eye and (d) an affected eye. e Slit lamp photograph of the anterior segment of an affected eye (a white precipitate is visible on the corneal endothelial side)
Detailed list of patients
| Case | Gender | Affected eye | Reduction rate (%) | Highest IOP (mmHg) | Pre Treat VA (log MAR) | Final MD (dB) | PCR | Ope |
|---|---|---|---|---|---|---|---|---|
| 1 | M | L | -1.5 | 31 | -0.1 | NP | − | − |
| 2 | F | R | 4.4 | 35 | 0.1 | NP | − | − |
| 3 | F | R | 7 | 14 | -0.1 | −0.32 | − | − |
| 4 | F | R | 9.7 | 27 | 0.2 | NP | − | − |
| 5 | M | L | 15.6 | 19 | 1 | GP | − | − |
| 6 | M | R | 21.8 | 23 | −0.2 | -8.33 | CMV | − |
| 7 | F | R | 43.8 | 46 | 0.1 | −0.4 | − | − |
| 8 | F | R | 4.9 | 42 | −0.1 | −1.37 | − | − |
| 9 | M | R | 72.7 | 26 | 0 | −0.28 | − | − |
| 10 | M | R | 8.3 | 43 | −0.2 | −1.43 | − | − |
| 11 | F | L | 2.2 | 49 | −0.1 | −0.46 | − | − |
| 12 | F | L | 17.6 | 26 | −0.2 | 0.8 | − | − |
| 13 | M | R | 9.1 | 68 | 0.4 | −28.38 | − | + |
| 14 | F | L | 23.3 | 68 | −0.2 | -6.45 | CMV | + |
| 15 | M | R | 23.9 | 68 | −0.1 | −4.38 | − | + |
| 16 | F | R | 25 | 68 | 0.3 | −2.2 | − | + |
| 17 | M | R | 31.9 | 68 | 0 | −4.76 | − | + |
| 18 | M | R | 31.9 | 68 | 0.1 | −7.4 | − | + |
| 19 | M | L | 31.6 | 68 | -0.1 | GP | − | + |
| 20 | F | L | 40.8 | 68 | -0.1 | 1.67 | Parvo B19 | + |
| 21 | F | L | 59.6 | 68 | 0 | −5.25 | − | + |
| 22 | F | L | 74.6 | 68 | 0.5 | −6.31 | − | + |
| 23 | F | R | 7.8 | 68 | 0 | −16.9 | − | + |
| 24 | M | R | 32.6 | 68 | 0 | -6.17 | CMV | + |
| 25 | M | R | 4.4 | 68 | −0.2 | −26.27 | − | + |
| 26 | F | R | 28 | 68 | 0 | -19.82 | CMV | + |
| 27 | M | R | 8.8 | 68 | 0.5 | -30.85 | CMV | + |
| 28 | M | L | 45.6 | 42 | −0.2 | −27.65 | − | + |
| 29 | F | L | 64.7 | 42 | −0.1 | -6.57 | CMV | + |
| 30 | M | L | 9.7 | 34 | 0.2 | -24.98 | CMV | + |
| 31 | M | R | 25.3 | 44 | −0.2 | −14.16 | − | + |
| 32 | M | R | 62.3 | 46 | 0 | 17.34 | − | + |
| 33 | M | L | 26 | 43 | 0.4 | −22.478 | − | + |
IOP intraocular pressure; VA visual acuity; MD mean deviation; M male; F female; NP not performed; GP Goldmann perimetry; CMV cytomegalovirus; TLE trabeculectomy; TLO trabeculotomy; TTO trabecutome
Fig. 2a CEC reduction (%) in the non-surgical and surgical groups (*p < 0.05). b Comparison of the maximum IOP in the non-surgical and surgical groups (**p < 0.01). c Comparison of the Humphrey visual field analyser-measured mean deviation in the non-surgical and surgical groups (**p < 0.01)
Fig. 3Correlation between reduced CEC density and attack frequency (r = 0.17, p = 0.46)
Fig. 4a Receiver operator curve (ROC) space for reduced CEC density. b Comparison of the number of patients who required filtration surgery in the high CEC reduction ratio CEC density and low CEC reduction ratio groups (**p < 0.01)